Selpercatinib
103 interactions 8 explained in plain English
Also sold as:
Retevmo
Retevmo®
About Selpercatinib
Selpercatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to nearby tissues or other parts of the body. It is also used to treat a certain type of thyroid cancer in adults and children 12 years of age and older that has spread to other parts of the body. Selpercatinib… Read the full Selpercatinib drug information page →
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Jun 30, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Most serious with:
Ketoconazole Topical
Oxaliplatin Injection
Axitinib
Felbamate
Eribulin Injection
Levofloxacin Injection
Contraindicated
Selpercatinib Ketoconazole Topical Extina® Foam Increased selpercatinib exposure and an increased risk of QT interval prolongation DetailsMajor
Selpercatinib Clindamycin ANTIROBE Explained Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Omeprazole Gastrobim Explained Reduced selpercatinib exposure and reduced anti-tumor activity Details Selpercatinib Amitriptyline Elavil Explained Increased risk of QT interval prolongation Details Selpercatinib Sertraline Explained Increased risk of QT interval prolongation Details Selpercatinib Buprenorphine Belbuca Explained Increased risk of QT interval prolongation Details Selpercatinib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Selpercatinib Colchicine Colcrys Explained Increased CYP3A and P-gp substrate with NTI exposure and an increased risk of CYP3A and P-gp with NTI-related adverse events Details Selpercatinib Abemaciclib Verzenio Explained Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Acalabrutinib Calquence Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Amisulpride Injection Barhemsys Increased risk of QT interval prolongation Details Selpercatinib Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Selpercatinib Aripiprazole Injection Abilify Increased risk of QT interval prolongation Details Selpercatinib Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Selpercatinib Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Selpercatinib Azithromycin AzaSite Increased risk of QT interval prolongation Details Selpercatinib Alfuzosin UroXatral Increased risk of QT interval prolongation Details Selpercatinib Anagrelide Agrylin Increased risk of QT interval prolongation Details Selpercatinib Axitinib Inlyta Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Bedaquiline Sirturo Increased risk of QT interval prolongation Details Selpercatinib Bosutinib Bosulif Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Brigatinib Alunbrig Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Chloroquine Aralen® Increased risk of QT interval prolongation Details Selpercatinib Clindamycin Injection ANTIROBE Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Clindamycin Topical C/T/S® Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Clindamycin Vaginal Cleocin Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Cobimetinib Cotellic Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Cyclosporine Injection Atopica Increased exposure of selpercatinib and cycloSPORINE and increased risk of adverse effects Details Selpercatinib Cyclosporine Ophthalmic Cequa Increased exposure of selpercatinib and cycloSPORINE and increased risk of adverse effects Details Selpercatinib Dasatinib Phyrago Increased substrate exposure, an increased risk of adverse reaction and an increased risk of QT interval prolongation Details Selpercatinib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Selpercatinib Deutetrabenazine Austedo Increased risk of QT interval prolongation Details Selpercatinib Dexlansoprazole Dexilant Reduced selpercatinib exposure and reduced anti-tumor activity Details Selpercatinib Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse effects Details Selpercatinib Dihydroergotamine Injection DHE-45® Injection Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Dihydroergotamine Nasal Spray Migranal Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Disopyramide Norpace Increased risk of QT interval prolongation Details Selpercatinib Docetaxel Beizray Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Docetaxel Injection Beizray Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Dofetilide Tikosyn Increased substrate exposure, an increased risk of adverse reaction and an increased risk of QT interval prolongation DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.